NPH to insulin glargine and combining the effect of HbA1c and hypoglycaemia reduction. METHODS: A discrete event life time simulation with microvascular complications incorporated via the DCCT (Diabetes Control and Complications Trial) study and cardiovascular events modelled using the Framingham equations was adapted to include the combined effects of HbA1c and hypoglycaemia reduction using published meta-regression results from 11 randomised clinical trials. Direct costs and quality of life (EQ5D) were derived from published sources and the HODaR database respectively; costs and benefits were discounted annually at 3.5%. The model was adapted to the profile of T1DM patients switched from NPH to glargine identified via the THIN database. Analysis was conducted on a total of 383 patients with data for the 12 month period prior to, and post switch; using primary outcome measure of adjusted Hba1c change. As hypoglycaemia was not directly collected from the THIN database a sensitivity analysis was performed taking into account HbA1c benefit only. RESULTS: The median age of patients switched from NPH to glargine was 34 years with mean duration of T1DM of 11.4 years. Baseline HbA1c was 8.71% and patients switching to glargine showed a reduction in HbA1c of 0.195% (p = 0.0045) between switch and 12-months post initiation. In a simulated cohort of 10,000 the discounted incremental cost effectiveness ratio (ICER) was Յ3,665 per quality adjusted life year gained (QALY). In sensitivity analysis using HbA1c benefit only the ICER was Յ9,411. CONCLUSION: Based on real life observational data, switching to glargine is cost-effective when compared to NPH; with a corresponding ICER well within accepted thresholds, even in sensitivity analysis using HbA1c effect only. OBJECTIVES: In a multinational, multicenter, observational study (PRESENT), patients treated with human premix insulin (with or without conventional oral medication) were converted to biphasic insulin aspart 30 (BIAsp 30) whilst maintaining their existing oral therapy. A sub-analysis (involving 1219 patients) demonstrated an improvement six months after therapy conversion of 1.66%-point in HbA1c and a reduced rate of hypoglycemic events (1079.8 to 290.2 per 100 patient years). METHODS: The published and validated CORE Diabetes Model was used to make long-term projections of clinical and cost outcomes based on patient characteristics (mean age 56.8 years, duration of diabetes 10.2 years, HbA1c 9.1%, BMI 28.7 kg.m-2) and treatment effects from PRESENT. Spanish mortality rates, baseline complications and costs of treating complications were derived from published sources. Transition probabilities were based on data from landmark clinical and epidemiological studies. Total direct costs (complications + treatment costs) were projected over patient lifetimes from a Spanish health care payer's perspective with future costs and clinical benefits discounted at 3.5% annually. RESULTS: Long-term projections indicated that BIAsp 30 treatment was associated with an improvement in discounted life expectancy of 0.77 years (11.33 Ϯ 0.15 versus 10.57 Ϯ 0.14 years). Taking quality of life into account led to a projected improvement of 1.03 quality-adjusted life years (QALYs) with BIAsp 30 over human premix insulin (7.83 Ϯ 0.11 versus 6.80 Ϯ 0.09 QALYs). Superior glycemic control associated with BIAsp 30 treatment was also projected to lead to fewer diabetesrelated complications and a net reduction in total direct medical costs of €8339 (€32,107 Ϯ 1030 versus €40,446 Ϯ 1247). CON-CLUSION: Higher pharmacy costs associated with BIAsp 30 treatment were offset by savings in the costs associated with diabetes-related complications versus human premix insulin. This resulted in a dominant scenario, where BIAsp 30 was associated with improved clinical outcomes and reduced costs compared to human premix insulin in the Spanish setting. OBJECTIVES: An internal study showed the relative risk of stroke was 0.800 and of MI was 0.621 for PIO based therapies versus non-TZD. Reduced MI and stroke events may drive reduced health care costs. Our objective was to compare health care costs in T2DM patients treated with PIO based versus non-TZD based therapies who had no prior MI or stroke events. METHODS: A retrospective cohort analysis was conducted using US health plan data (I3Innovus) from January 1, 2003 to June 30, 2006. Initial ICD-9 codes for T2DM (250.x0 and 250.x2) defined patient index date. The PIO group included patients treated with PIO combined with any other antidiabetic agents (excluding rosiglitazone). The non-TZD group included patients treated with any antidiabetic treatment, but not TZDs. Inclusion criteria were: age Ն45 years, continuous enrollment for at least 6 months before and 1 month after the index date, no history of stroke or MI in the last six months and documented medical claims after the index date. Stroke and MI were defined by appropriate ICD-9 codes. We fitted a generalized linear model with log link and gamma distribution to the monthly average cost in 1] stroke and [2] MI cohorts, controlling for age, hypertension, and hypercholesteremia. RESULTS: In the stroke cohort, mean total health care cost per patient per month was $1,839 in the PIO group versus $2,115 in the non-TZD group (p < 0.0001). In the MI cohort, mean total health care cost per patient per month was $1,843 in the PIO group versus $2,191 in the non-TZD group (p < 0.0001). Mean medical cost per patient per month in the stroke and MI cohorts was 20% and 23% less, respectively, in the PIO group compared to the non-TZD group. CONCLUSION: PIO based therapies are associated with significantly lower medical and total health care costs compared to those not treated with TZDs in MI and stroke cohorts. OBJECTIVES: Data from the PREDICTIVE study indicated that, in type 2 diabetes patients receiving long-acting insulin therapy Ϯ oral hypoglycemic agents (OHAs), therapy conversion from insulin glargine to insulin detemir was associated with Abstracts A263
NPH to insulin glargine and combining the effect of HbA1c and hypoglycaemia reduction. METHODS: A discrete event life time simulation with microvascular complications incorporated via the DCCT (Diabetes Control and Complications Trial) study and cardiovascular events modelled using the Framingham equations was adapted to include the combined effects of HbA1c and hypoglycaemia reduction using published meta-regression results from 11 randomised clinical trials. Direct costs and quality of life (EQ5D) were derived from published sources and the HODaR database respectively; costs and benefits were discounted annually at 3.5%. The model was adapted to the profile of T1DM patients switched from NPH to glargine identified via the THIN database. Analysis was conducted on a total of 383 patients with data for the 12 month period prior to, and post switch; using primary outcome measure of adjusted Hba1c change. As hypoglycaemia was not directly collected from the THIN database a sensitivity analysis was performed taking into account HbA1c benefit only. RESULTS: The median age of patients switched from NPH to glargine was 34 years with mean duration of T1DM of 11.4 years. Baseline HbA1c was 8.71% and patients switching to glargine showed a reduction in HbA1c of 0.195% (p = 0.0045) between switch and 12-months post initiation. In a simulated cohort of 10,000 the discounted incremental cost effectiveness ratio (ICER) was Յ3,665 per quality adjusted life year gained (QALY). In sensitivity analysis using HbA1c benefit only the ICER was Յ9,411. CONCLUSION: Based on real life observational data, switching to glargine is cost-effective when compared to NPH; with a corresponding ICER well within accepted thresholds, even in sensitivity analysis using HbA1c effect only.
PDB30 EVALUATING THE COST-EFFECTIVENESS OF BIPHASIC INSULIN ASPART 30 VERSUS HUMAN PREMIX INSULIN FOR THE TREATMENT OF TYPE 2 DIABETES IN A SPANISH SETTING
Tucker D 1 ,Valentine WJ 1 , Nielsen S 2 , Townsend C 2 , Kotchie R 3 , Scheijbeler H 3 1 IMS Health, Basel, Switzerland, 2 Novo Nordisk A/S, Virum, Denmark, 3 IMS Health, London, UK OBJECTIVES: In a multinational, multicenter, observational study (PRESENT), patients treated with human premix insulin (with or without conventional oral medication) were converted to biphasic insulin aspart 30 (BIAsp 30) whilst maintaining their existing oral therapy. A sub-analysis (involving 1219 patients) demonstrated an improvement six months after therapy conversion of 1.66%-point in HbA1c and a reduced rate of hypoglycemic events (1079.8 to 290.2 per 100 patient years). METHODS: The published and validated CORE Diabetes Model was used to make long-term projections of clinical and cost outcomes based on patient characteristics (mean age 56.8 years, duration of diabetes 10.2 years, HbA1c 9.1%, BMI 28.7 kg.m-2) and treatment effects from PRESENT. Spanish mortality rates, baseline complications and costs of treating complications were derived from published sources. Transition probabilities were based on data from landmark clinical and epidemiological studies. Total direct costs (complications + treatment costs) were projected over patient lifetimes from a Spanish health care payer's perspective with future costs and clinical benefits discounted at 3.5% annually. RESULTS: Long-term projections indicated that BIAsp 30 treatment was associated with an improvement in discounted life expectancy of 0.77 years (11.33 Ϯ 0.15 versus 10.57 Ϯ 0.14 years). Taking quality of life into account led to a projected improvement of 1.03 quality-adjusted life years (QALYs) with BIAsp 30 over human premix insulin (7.83 Ϯ 0.11 versus 6.80 Ϯ 0.09 QALYs). Superior glycemic control associated with BIAsp 30 treatment was also projected to lead to fewer diabetesrelated complications and a net reduction in total direct medical costs of €8339 (€32,107 Ϯ 1030 versus €40,446 Ϯ 1247). CON-CLUSION: Higher pharmacy costs associated with BIAsp 30 treatment were offset by savings in the costs associated with diabetes-related complications versus human premix insulin. This resulted in a dominant scenario, where BIAsp 30 was associated with improved clinical outcomes and reduced costs compared to human premix insulin in the Spanish setting.
PDB31 TOTAL COST REDUCTION IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS TREATED WITH PIOGLITAZONE (PIO) BASED THERAPIES VERSUS NON-THIAZOLIDINEDIONE (NON-TZD) BASED THERAPIES
Baran RW, Xu Y,Vallarino C, Pandya B Takeda Global Research and Development Center, Inc, Deerfield, IL, USA OBJECTIVES: An internal study showed the relative risk of stroke was 0.800 and of MI was 0.621 for PIO based therapies versus non-TZD. Reduced MI and stroke events may drive reduced health care costs. Our objective was to compare health care costs in T2DM patients treated with PIO based versus non-TZD based therapies who had no prior MI or stroke events. METHODS: A retrospective cohort analysis was conducted using US health plan data (I3Innovus) from January 1, 2003 to June 30, 2006. Initial ICD-9 codes for T2DM (250.x0 and 250.x2) defined patient index date. The PIO group included patients treated with PIO combined with any other antidiabetic agents (excluding rosiglitazone). The non-TZD group included patients treated with any antidiabetic treatment, but not TZDs. Inclusion criteria were: age Ն45 years, continuous enrollment for at least 6 months before and 1 month after the index date, no history of stroke or MI in the last six months and documented medical claims after the index date. Stroke and MI were defined by appropriate ICD-9 codes. We fitted a generalized linear model with log link and gamma distribution to the monthly average cost in 1] stroke and [2] MI cohorts, controlling for age, hypertension, and hypercholesteremia. RESULTS: In the stroke cohort, mean total health care cost per patient per month was $1,839 in the PIO group versus $2,115 in the non-TZD group (p < 0.0001). In the MI cohort, mean total health care cost per patient per month was $1,843 in the PIO group versus $2,191 in the non-TZD group (p < 0.0001). Mean medical cost per patient per month in the stroke and MI cohorts was 20% and 23% less, respectively, in the PIO group compared to the non-TZD group. CONCLUSION: PIO based therapies are associated with significantly lower medical and total health care costs compared to those not treated with TZDs in MI and stroke cohorts.
PDB32 EVALUATING THE LONG-TERM CLINICAL AND ECONOMIC IMPLICATIONS OF CONVERTING TYPE 2 DIABETES PATIENTS TO INSULIN DETEMIR (ϮORAL HYPOGLYCEMIC AGENTS) FROM INSULIN GLARGINE BASED REGIMENS IN GERMANY; DATA FROM THE PREDICTIVE STUDY
Valentine WJ 1 , Goodall G 1 , Aagren M 2 , Nielsen S 2 , Kotchie R 3 1 IMS Health, Basel, Switzerland, 2 Novo Nordisk A/S, Virum, Denmark, 3 IMS Health, London, UK OBJECTIVES: Data from the PREDICTIVE study indicated that, in type 2 diabetes patients receiving long-acting insulin therapy Ϯ oral hypoglycemic agents (OHAs), therapy conversion from insulin glargine to insulin detemir was associated with Abstracts A263 significant improvements in glycemic control (HbA1c 0.59%) and body weight (BMI 0.52 kg.m-2). The aim of this analysis was to estimate the long-term clinical and cost implications associated with therapy conversion from insulin glargine to detemir in type 2 diabetes patients in Germany. METHODS: A previously published and validated diabetes model (CORE Diabetes Model) was used to make long-term projections of clinical and cost outcomes based on patient characteristics (age 62.3 years, duration of diabetes 7 years, HbA1c 8.30%, 50.4% male) and treatment effects from the German part of PREDICTIVE. The model was used to estimate life-expectancy, quality-adjusted life expectancy and to account direct medical costs (pharmacy, patient management and complication costs). Costs were derived from published sources and expressed in 2006 Euros. Future costs and clinical benefits were discounted at 5% annually. RESULTS: Therapy conversion from insulin glargine to insulin detemir was projected to improve life expectancy by approximately 0.13 years (7.08 Ϯ 0.13 versus 6.95 Ϯ 0.12 years) and quality-adjusted life expectancy by 0.29 quality-adjusted life years (QALYs) (4.53 Ϯ 0.09 versus 4.24 Ϯ 0.08 QALYs). Direct costs associated with insulin detemir treatment were projected to be lower over patient lifetimes than with glargine (€ 54,807 Ϯ 1,788 versus € 55,839 Ϯ 1,749 per patient, difference € 1,032). Cost savings were driven by lower complication costs (due to HbA1c improvements) associated with insulin detemir. CONCLUSION: Modeling the long-term implications of therapy conversion from insulin glargine to detemir based on data from German patients in PREDICTIVE indicates that insulin detemir is associated with benefits in terms of life expectancy, qualityadjusted life expectancy and complication rates, as well as reducing costs from a third-party health care payer perspective in Germany.
PDB33 COST EFFECTIVENESS OF JANUVIA VERSUS AVANDIA AS SUPPLEMENTARY TREATMENT IN COMBINATION WITH METFORMIN FOR PATIENTS WITH TYPE 2 DIABETES
Verheggen BG 1 ,Van der Steen A 1 , Heeg BMS 1 ,Vos CBJ 2 , Van Hout BA 1 1 Pharmerit BV, Rotterdam, The Netherlands, 2 Merck Sharp & Dohme BV, Haarlem, The Netherlands OBJECTIVES: To assess the costs and effects of Januvia versus Avandia as supplementary treatment in combination with metformin, for patients with type 2 diabetes in whom metformin (in addition to diet and exercise) does not provide adequate glycemic control. METHODS: The Disease Elimination Life Table Analysis (DELTA) cohort model was used to assess the costs and effects of Januvia (100 mg) in comparison to Avandia (8 mg). The model contains five sub models representing diabetes related complications. Estimates of disease progression, incidence in the sub models, disease related mortality, and all cause mortality, were derived from the UK Prospective Diabetes Study. Estimates regarding drug efficacy and adverse events were based on an 18-week head-to-head comparison of Januvia 100 mg versus Avandia 8 mg supplementary to metformin. The analysis was conducted from a societal perspective. Direct and indirect costs were included. Effects were reported as (disease-free) life years and quality-adjusted life years (QALY). To determine the robustness of the model and the impact of uncertainty, uni-and multivariate sensitivity analyses were carried out. RESULTS: Januvia is estimated to be the dominant treatment when compared to Avandia 8 mg. The univariate sensitivity analyses revealed this conclusion to be robust over a wide range of values. Results from the multivariate sensitivity analysis estimate the probability that Januvia combines additional effectiveness with cost savings at 59%, the probability that Januvia gains QALYs at additional costs at 13%. The probability that Januvia is less effective is estimated at 28% (15% with cost savings and in 13% with additional costs). CONCLUSION: Conditional on the correctness of the estimates and assumptions made, Januvia 100 mg is dominant over 8 mg Avandia. Sensitivity analyses suggest results are robust to reasonable changes in input parameters.
PDB34

LONG-TERM COST-EFFECTIVENESS ANALYSIS OF A MODERN INSULIN IN PATIENTS WITH POORLY CONTROLLED TYPE 2 DIABETES IN THE GERMAN SETTING; DATA FROM THE PREDICTIVE STUDY
Palmer JL 1 , Goodall G 1 , Aagren M 2 , Nielsen S 2 , Kotchie R 3 , Valentine WJ 1 1 IMS Health, Basel, Switzerland, 2 Novo Nordisk A/S, Virum, Denmark, 3 IMS Health, London, UK OBJECTIVES: The aim of this analysis was to project the longterm clinical and economic outcomes associated with therapy conversion to insulin detemir from Neutral Protamine Hagedorn (NPH) insulin in patients with type 2 diabetes in the German setting. METHODS: A previously published and validated computer simulation model of diabetes was used to make long-term projections of clinical and cost outcomes based on patient characteristics and treatment effects from a sub-analysis of the PRE-DICTIVE study. Data from PREDICTIVE indicated that therapy conversion from NPH insulin to insulin detemir was associated with significant improvements in glycemic control (HbA1c -0.6%) and reduced weight gain (body mass index -0.382 kg/ m 2 ). Based on these clinical findings, the computer simulation model was used to estimate life-expectancy, quality-adjusted life expectancy and costs from a third party healthcare payer perspective. Future costs and clinical benefits were discounted at 5% per annum. RESULTS: Conversion to insulin detemir was projected to improve life expectancy by approximately 0.13 years compared to NPH (7.08 Ϯ 0.13 versus 6.95 Ϯ 0.12 years) and quality-adjusted life expectancy by 0.28 quality-adjusted life years (QALYs) (4.51 Ϯ 0.09 versus 4.23 Ϯ 0.08 QALYs). Direct medical costs over patient lifetimes were projected to be marginally lower in patients receiving insulin detemir compared to NPH (€ 54,575 Ϯ 1,842 versus € 54,640 Ϯ 1,739, difference € 65 per patient). Pharmacy costs were higher with insulin detemir (€ 14,129 versus € 12,230, difference € 1,899) but were more than offset by cost savings due to complications avoided (complication costs € 38,246 versus € 40,242, difference € 1,996). CONCLUSIONS: This modeling study, based on a German subanalysis of PREDICTIVE, suggests that therapy conversion from NPH to insulin detemir is likely to be associated with long-term clinical benefits and may well be cost saving in type 2 diabetes patients in the German setting.
PDB35 ECONOMIC ANALYSIS OF THE TREATMENT WITH INSULIN GLARGINE PLUS ORAL ANTIDIABETICS (BOT) COMPARED TO TWICE DAILY PREMIXED INSULIN (CT) BASED ON THE LAPTOP TRIAL
Janka HU 1 , Hessel F 2 , Walzer S 3 , Mueller E 3 1 Zentralkrankenhaus Bremen-Nord, Bremen, Germany, 2 Sanofi-Aventis, Berlin, Germany, 3 Analytica International, Loerrach, Germany OBJECTIVES: Based on the clinical results of the LAPTOP trial, a cost analysis from the perspective of the German Statutory Health Insurance (SHI) was performed. In addition a model simulation of the long term complications was conducted using
